Cost-effectiveness analysis of 13-valent pneumococcal conjugate vaccine versus 23-valent pneumococcal polysaccharide vaccine in an adult population in South Korea

References

• Atlas RM, Wellnitz WR. Microorganisms in our world. St Louis: Mosby-Year Book; 1995.
   Google Scholar
• Center for Disease Control and Prevention. Pneumococcal home, about pneumococcal. [2017 Mar 21]. https://www.cdc.gov/pneumococcal/about/symptoms-complications.html.
   Google Scholar
• Huss A, Scott P, Stuck AE, Trotter C, Egger M. Efficacy of pneumococcal vaccination in adults: a meta-analysis. Can Med Assoc J. 2009;180(1):48–58. doi:10.1503/cmaj.080734.
   PubMed Web of Science ®Google Scholar
• Atkinson W, Wolfe S, Hamborsky J. Centers for Disease Control and Prevention Epidemiology and Prevention of Vaccine-preventable Diseases,“Pink Book,”. Washington, DC: Public Health Foundation; 2011.
   Google Scholar
• Huang SS, Johnson KM, Ray GT, Wroe P, Lieu TA, Moore MR, Zell ER, Linder JA, Grijalva CG, Metlay JP. Healthcare utilization and cost of pneumococcal disease in the United States. Vaccine. 2011;29(18):3398–412. doi:10.1016/j.vaccine.2011.02.088. PMID:21397721.
   PubMed Web of Science ®Google Scholar
• Weycker D, Strutton D, Edelsberg J, Sato R, Jackson LA. Clinical and economic burden of pneumococcal disease in older US adults. Vaccine. 2010;28(31):4955–60. doi:10.1016/j.vaccine.2010.05.030. PMID:20576535.
   PubMed Web of Science ®Google Scholar
• Choi MJ, Song JY, Noh JY, Yoon JG, Hyun HJ, Yun JW, Kim WJ, Cheong HJ. Disease Burden and Risk Factors of Hospitalized Community-Acquired Pneumonia in Korean Adults. IDWeek 2016. New Orleans, LA: LA Infectious Diseases Society of America; 2016.
   Google Scholar
• Woo JH, Kang JM, Kim YS, Shin WS, Ryu JH, Choi JH, Kim YR, Cheong HJ, Uh ST, Park CS. A prospective multicenter study of community-acquired pneumonia in adults with emphasis on bacterial etiology. Korean J Infect Dis. 2001;33(1):1–7.
   Google Scholar
• Chong YP, Jung K-S, Lee KH, Kim M-N, Moon SM, Park S, Hur J, Kim D-M, Jeon MH, Woo JH. The bacterial etiology of community-acquired pneumonia in Korea: a nationwide prospective multicenter study. Infect Chemother. 2010;42(6):397–403. doi:10.3947/ic.2010.42.6.397.
   Google Scholar
• Yoo KH, Yoo CG, Kim SK, Jung JY, Lee MG, Uh ST, Shim TS, Jeon K, Shim JJ, Lee HB. Economic burden and epidemiology of pneumonia in Korean adults aged over 50 years. J Korean Med Sci. 2013;28(6):888–95. doi:10.3346/jkms.2013.28.6.888. PMID:23772154.
   PubMed Web of Science ®Google Scholar
• Chung MH, Shin WS, Kim YR, Kang MW, Kim MJ, Jung HJ, Park SC, Pai H, Choi HJ, Shin HS. Etiology of community-acquired pneumonia surveyed by 7 university hospitals. Korean J Infect Dis. 1997;29(5):339–59.
   Google Scholar
• Choi MJ, Song JY, Cheong HJ, Jeon JH, Kang SH, Jung EJ, Noh JY, Kim WJ. Clinical usefulness of pneumococcal urinary antigen test, stratified by disease severity and serotypes. J Infect and Chemother. 2015;21(9):672–9. doi:10.1016/j.jiac.2015.06.003.
   PubMed Web of Science ®Google Scholar
• Yu CW, Park CW, Hwang BY, Song JY, Park O, Sohn JW, Cheong HJ, Kim WJ, Kim MJ, Park SC. Clinical features and prognosisof community-acquired pneumonia in the elderly patients. Korean J Infect Dis. 2000;32(3):212–8.
   Google Scholar
• Sohn JW, Park SC, Choi Y-H, Woo HJ, Cho YK, Lee JS, Sim H-S, Kim MJ. Atypical Pathogens as Etiologic Agents in Hospitalized Patient with Community-Acquired Pneumonia in Korea: A Prospective Multi-Center Study. J Korean Med Sci. 2006;21(4):602–7. doi:10.3346/jkms.2006.21.4.602. PMID:16891800.
   PubMed Web of Science ®Google Scholar
• Song J-H, Oh WS, Kang C-I, Chung DR, Peck KR, Ko KS, Yeom JS, Kim CK, Kim SW, Chang H-H. Epidemiology and clinical outcomes of community-acquired pneumonia in adult patients in Asian countries: a prospective study by the Asian network for surveillance of resistant pathogens. Int J Antimicrob Agents. 2008;31(2):107–14. doi:10.1016/j.ijantimicag.2007.09.014. PMID:18162378.
   PubMed Web of Science ®Google Scholar
• Jeon EJ, Cho S-G, Shin JW, Kim JY, Park IW, Choi BW, Choi JC. The difference in clinical presentations between healthcare-associated and community-acquired pneumonia in university-affiliated hospital in Korea. Yonsei Med J. 2011;52(2):282–7. doi:10.3349/ymj.2011.52.2.282. PMID:21319347.
   PubMed Web of Science ®Google Scholar
• Lee JS, Chung JW, Koh Y, Lim C-M, Jung YJ, Oh YM, Shim TS, Lee SD, Kim WS, Kim D-S. The etiologies and initial antimicrobial therapy outcomes in one tertiary hospital ICU-admitted patient with severe community-acquired pneumonia. Tuberc Respir Dis. 2005;59(5):522–9. doi:10.4046/trd.2005.59.5.522.
   Google Scholar
• Oh SY, Park SJ, Koh YM, Suh GY, Chung MP, Kim H, Choi DC, Kwon OJ, Rhee CH. Efficacy of the antibiotics chosen by ATS guideline in the treatment of Korean patients with community-acquired pneumonia admitted to a tertiary hospital. Tuberc Respir Dis. 1999;47(4):460–70. doi:10.4046/trd.1999.47.4.460.
   Google Scholar
• Song JY, Choi JY, Lee JS, Bae I-G, Kim YK, Sohn JW, Jo YM, Choi WS, Lee J, Park KH. Clinical and economic burden of invasive pneumococcal disease in adults: a multicenter hospital-based study. BMC Infect Dis. 2013;13(1):202. doi:10.1186/1471-2334-13-202. PMID:23641904.
   PubMed Web of Science ®Google Scholar
• van Hoek AJ, Andrews N, Waight PA, Stowe J, Gates P, George R, Miller E. The effect of underlying clinical conditions on the risk of developing invasive pneumococcal disease in England. J Infect. 2012;65(1):17–24. doi:10.1016/j.jinf.2012.02.017. PMID:22394683.
   PubMed Web of Science ®Google Scholar
• Kyaw MH, Rose Jr CE, Fry AM, Singleton JA, Moore Z, Zell ER, Whitney CG, Network ABCSPotEIP. The influence of chronic illnesses on the incidence of invasive pneumococcal disease in adults. J Infect Dis. 2005;192(3):377–86. doi:10.1086/431521. PMID:15995950.
   PubMed Web of Science ®Google Scholar
• Song JH, Jung SI, Ko KS, Kim NY, Son JS, Chang HH, Ki HK, Oh WS, Suh JY, Peck KR, et al. High prevalence of antimicrobial resistance among clinical Streptococcus pneumoniae isolates in Asia (an ANSORP study). Antimicrob Agents Chemother. 2004;48(6):2101–7. doi:10.1128/AAC.48.6.2101-2107.2004. PMID:15155207.
   PubMed Web of Science ®Google Scholar
• Fenoll A, Granizo JJ, Aguilar L, Gimenez MJ, Aragoneses-Fenoll L, Hanquet G, Casal J, Tarrago D. Temporal trends of invasive Streptococcus pneumoniae serotypes and antimicrobial resistance patterns in Spain from 1979 to 2007. J Clin Microbiol. 2009;47(4):1012–20. doi:10.1128/JCM.01454-08. PMID:19225097.
   PubMed Web of Science ®Google Scholar
• Reinert RR, van der Linden M, Seegmuller I, Al-Lahham A, Siedler A, Weissmann B, Toschke AM, von Kries R. Molecular epidemiology of penicillin-non-susceptible Streptococcus pneumoniae isolates from children with invasive pneumococcal disease in Germany. Clin Microbiol Infect. 2007;13(4):363–8. doi:10.1111/j.1469-0691.2006.01676.x. PMID:17359319.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Vaccines and preventable disease. [2017 Mar 21]. https://www.cdc.gov/vaccines/vpd/pneumo/.
   Google Scholar
• National Health Service. The NHS vaccination schedule. 2016. [2017 Mar 21]. http://www.nhs.uk/Conditions/vaccinations/Pages/vaccination-schedule-age-checklist.aspx.
   Google Scholar
• Australian Government Department of Health. Pneumococcal disease. [2017 Mar 21]. http://www.immunise.health.gov.au/internet/immunise/publishing.nsf/Content/immunise-pneumococcal.
   Google Scholar
• Korean Centers for Disease Control and Prevention. Pneumococcal vaccination program for the elderly. 2016 June 8. [Accessed 2017 June 6]. http://cdc.go.kr/CDC/notice/CdcKrTogether0302.jsp?menuIds=HOME001-MNU1154-MNU0005-MNU0088&cid=68718.
   Google Scholar
• Geno KA, Gilbert GL, Song JY, Skovsted IC, Klugman KP, Jones C, Konradsen HB, Nahm MH. Pneumococcal capsules and their types: past, present, and future. Clin Microbiol Rev. 2015;28(3):871–99. doi:10.1128/CMR.00024-15. PMID:26085553.
   PubMed Web of Science ®Google Scholar
• Vila-Corcoles A, Ochoa-Gondar O. Preventing Pneumococcal Disease in the Elderly. Drugs & Aging. 2013;30(5):263–76. doi:10.1007/s40266-013-0060-5.
   PubMed Web of Science ®Google Scholar
• Moberley S, Holden J, Tatham DP, Andrews RM. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev. 2013; doi:10.1002/14651858.CD000422.pub3.1):CD000422. doi:10.1002/14651858.CD000422.pub3. PMID:23440780.
   PubMed Web of Science ®Google Scholar
• Shapiro ED, Berg AT, Austrian R, Schroeder D, Parcells V, Margolis A, Adair RK, Clemens JD. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med. 1991;325(21):1453–60. doi:10.1056/NEJM199111213252101. PMID:1944423.
   PubMed Web of Science ®Google Scholar
• Schenkein JG, Park S, Nahm MH. Pneumococcal vaccination in older adults induces antibodies with low opsonic capacity and reduced antibody potency. Vaccine. 2008;26(43):5521–6. doi:10.1016/j.vaccine.2008.07.071. PMID:18706464.
   PubMed Web of Science ®Google Scholar
• Brynjolfsson SF, Henneken M, Bjarnarson SP, Mori E, Del Giudice G, Jonsdottir I. Hyporesponsiveness following booster immunization with bacterial polysaccharides is caused by apoptosis of memory B cells. J Infect Dis. 2012;205(3):422–30. doi:10.1093/infdis/jir750. PMID:22158565.
   PubMed Web of Science ®Google Scholar
• Clutterbuck EA, Lazarus R, Yu L-M, Bowman J, Bateman EA, Diggle L, Angus B, Peto TE, Beverley PC, Mant D. Pneumococcal conjugate and plain polysaccharide vaccines have divergent effects on antigen-specific B cells. J Infect Dis. 2012;205(9):1408–16. doi:10.1093/infdis/jis212. PMID:22457293.
   PubMed Web of Science ®Google Scholar
• Waight PA, Andrews NJ, Ladhani SN, Sheppard CL, Slack MP, Miller E. Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study. Lancet Infect Dis. 2015;15(5):535–43. doi:10.1016/S1473-3099(15)70044-7. PMID:25801458.
   PubMed Web of Science ®Google Scholar
• Hoshi S-l, Kondo M, Okubo I. Economic evaluation of immunisation programme of 23-valent pneumococcal polysaccharide vaccine and the inclusion of 13-valent pneumococcal conjugate vaccine in the list for single-dose subsidy to the elderly in Japan. PloS One. 2015;10(10):e0139140. doi:10.1371/journal.pone.0139140. PMID:26444287.
   PubMed Web of Science ®Google Scholar
• van Hoek AJ, Miller E. Cost-Effectiveness of Vaccinating Immunocompetent≥ 65 Year Olds with the 13-Valent Pneumococcal Conjugate Vaccine in England. PloS One. 2016;11(2):e0149540. doi:10.1371/journal.pone.0149540. PMID:26914907.
   PubMed Web of Science ®Google Scholar
• Blommaert A, Bilcke J, Willem L, Verhaegen J, Goossens H, Beutels P. The cost-effectiveness of pneumococcal vaccination in healthy adults over 50: An exploration of influential factors for Belgium. Vaccine. 2016;34(18):2106–12. doi:10.1016/j.vaccine.2016.03.003. PMID:26988257.
   PubMed Web of Science ®Google Scholar
• Stoecker C, Kim L, Gierke R, Pilishvili T. Incremental cost-effectiveness of 13-valent pneumococcal conjugate vaccine for adults age 50 years and older in the United States. J Gen Intern Med. 2016;31(8):901–8. doi:10.1007/s11606-016-3651-0. PMID:26976292.
   PubMed Web of Science ®Google Scholar
• Mangen M-JJ, Rozenbaum MH, Huijts SM, van Werkhoven CH, Postma DF, Atwood M, van Deursen AM, van der Ende A, Grobbee DE, Sanders EA. Cost-effectiveness of adult pneumococcal conjugate vaccination in the Netherlands. Eur Resp J. 2015;46(5):1407–16. doi:10.1183/13993003.00325-2015. PMID: 6160871.
   PubMed Web of Science ®Google Scholar
• Health Insurance Review & Assessment Service. Evaluation criteria for cost-effectiveness. Detailed evaluation criteria for drugs subject to negotiation including new drugs, etc., 2016. [accessed 2017 June 6]. http://www.hira.or.kr/dummy.do?pgmid=HIRAA020002000000&cmsurl=/cms/inform/01/1351466_27106.html#none.
   Google Scholar
• International Monetary Fund. World Economic Outlook update; 2016. [2017 June 6]. http://www.imf.org/external/pubs/ft/weo/2016/update/01/.
   Google Scholar
• Butler JC, Schuchat A. Epidemiology of pneumococcal infections in the elderly. Drugs & Aging. 1999;15(1):11–9. doi:10.2165/00002512-199915001-00002.
   PubMedGoogle Scholar
• Jokinen C, Heiskanen L, Juvonen H, Kallinen S, Karkola K, Korppi M, Kurki S, Rönnberg PR, Seppä A, Soimakallio S. Incidence of community-acquired pneumonia in the population of four municipalities in eastern Finland. Amer J Epidemiol. 1993;137(9):977–88. doi:10.1093/oxfordjournals.aje.a116770.
   PubMed Web of Science ®Google Scholar
• Bonten MJ, Huijts SM, Bolkenbaas M, Webber C, Patterson S, Gault S, van Werkhoven CH, van Deursen AM, Sanders EA, Verheij TJ. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med. 2015;372(12):1114–25. doi:10.1056/NEJMoa1408544. PMID:25785969.
   PubMed Web of Science ®Google Scholar
• Tomczyk S, Bennett NM, Stoecker C, Gierke R, Moore MR, Whitney CG, Hadler S, Pilishvili T, Control CfD, Prevention. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged≥ 65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2014;63(37):822–5. PMID:25233284.
   PubMed Web of Science ®Google Scholar
• Korea Statistical Information Service. Population by age, 2016. [2016 July 27]. http://kosis.kr/statisticsList/statisticsList_01List.jsp?vwcd=MT_ZTITLE&parentId=A#SubCont.
   Google Scholar
• Kim MJ. Pneumococcal diseases and serotyping in the population over 65 years old in Korea. Korean Centers for Disease Control and Prevention. 2015. [2018 April 26]. http://www.prism.go.kr/homepage/entire/retrieveEntireDetail.do;jsessionid=087D85E7CB9309D4BED478809629F098.node02?cond_research_name=&cond_research_start_date=&cond_research_end_date=&research_id=1351000-201400151&pageIndex=288&leftMenuLevel=160.
   Google Scholar
• Heo JY, Seo YB, Choi WS, Lee J, Noh JY, Jeong HW, Kim WJ, Kim MJ, Lee HY, Song JY. Incidence and mortality of community-acquired pneumonia and pneumococcal diseases among Korean adults: catchment population-based analysis. The 10th International Symposium on Pneumococci and Pneumococcal Diseases 2016; Glasgow, Scotland: ISPPD Association.
   Google Scholar
• Center for Disease Control and Prevention. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. Morbidity and Mortality Weekly Report. 2012;61(40):816. PMID:23051612.
   PubMedGoogle Scholar
• Kim HI, Kim SW, Chang HH, Cha SI, Lee JH, Ki HK, Cheong HS, Yoo KH, Ryu SY, Kwon KT, et al. Mortality of community-acquired pneumonia in Korea: assessed with the pneumonia severity index and the CURB-65 score. J Korean Med Sci. 2013;28(9):1276–82. doi:10.3346/jkms.2013.28.9.1276. PMID:24015030.
   PubMed Web of Science ®Google Scholar
• Kang C-I, Song J-H, Kim SH, Chung DR, Peck KR, Thamlikitkul V, Wang H, So TM-k, Hsueh P-R, Yasin RM. Risk factors and pathogenic significance of bacteremic pneumonia in adult patients with community-acquired pneumococcal pneumonia. J Infect. 2013;66(1):34–40. doi:10.1016/j.jinf.2012.08.011. PMID:22922634.
   PubMed Web of Science ®Google Scholar
• National Health Statistics. 2014. [2018 February 2]. https://www.seoulmentalhealth.kr/dataroom/data.jsp?cmd=view&test_num=88.
   Google Scholar
• Smith KJ, Wateska AR, Nowalk MP, Raymund M, Nuorti JP, Zimmerman RK. Cost-effectiveness of adult vaccination strategies using pneumococcal conjugate vaccine compared with pneumococcal polysaccharide vaccine. JAMA. 2012;307(8):804–12. doi:10.1001/jama.2012.169. PMID:22357831.
   PubMed Web of Science ®Google Scholar
• Jiang Y, Gauthier A, Keeping S, Carroll S. Cost-effectiveness of vaccinating the elderly and at-risk adults with the 23-valent pneumococcal polysaccharide vaccine or 13-valent pneumococcal conjugate vaccine in the UK. Expert Rev Pharmacoecon Outcomes Res. 2014;14(6):913–27. doi:10.1586/14737167.2014.950232. PMID:25189087.
   PubMed Web of Science ®Google Scholar
• Klugman KP, Madhi SA, Huebner RE, Kohberger R, Mbelle N, Pierce N. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med. 2003;349(14):1341–8. doi:10.1056/NEJMoa035060. PMID:14523142.
   PubMed Web of Science ®Google Scholar
• French N, Nakiyingi J, Carpenter L, Lugada E, Watera C, Moi K, Moore M, Antvelink D, Mulder D, Janoff E. 23–valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial. Lancet. 2000;355(9221):2106–11. doi:10.1016/S0140-6736(00)02377-1. PMID:10902624.
   PubMed Web of Science ®Google Scholar
• Advisory Committee on Immunization Practices, Summary report, June 20–21. Atlanta: Centers for Disease control and prevention; 2012.
   Google Scholar
• Ochoa-Gondar O, Vila-Corcoles A, Rodriguez-Blanco T, Gomez-Bertomeu F, Figuerola-Massana E, Raga-Luria X. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against community-acquired pneumonia in the general population aged≥ 60 years: 3 years of follow-up in the CAPAMIS study. Clin Infect Dis. 2014;58(7):909–17. doi:10.1093/cid/ciu002. PMID:24532544.
   PubMed Web of Science ®Google Scholar
• Vila-Corcoles A, Salsench E, Rodriguez-Blanco T, Ochoa-Gondar O, de Diego C, Valdivieso A, Hospital I, Gomez-Bertomeu F, Raga X. Clinical effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumonia in middle-aged and older adults: a matched case–control study. Vaccine. 2009;27(10):1504–10. doi:10.1016/j.vaccine.2009.01.013. PMID:19171174.
   PubMed Web of Science ®Google Scholar
• Pilishvili T, Lexau C, Farley MM, Hadler J, Harrison LH, Bennett NM, Reingold A, Thomas A, Schaffner W, Craig AS. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis. 2010;201(1):32–41. doi:10.1086/648593. PMID:19947881.
   PubMed Web of Science ®Google Scholar
• Feikin DR, Kagucia EW, Loo JD, Link-Gelles R, Puhan MA, Cherian T, Levine OS, Whitney CG, O'Brien KL, Moore MR. Serotype-specific changes in invasive pneumococcal disease after pneumococcal conjugate vaccine introduction: a pooled analysis of multiple surveillance sites. PLoS Med. 2013;10(9):e1001517. doi:10.1371/journal.pmed.1001517. PMID:24086113.
   PubMed Web of Science ®Google Scholar
• Choe YJ, Yang JJ, Park SK, Choi EH, Lee HJ. Comparative estimation of coverage between national immunization program vaccines and non-NIP vaccines in Korea. J Korean Med Sci. 2013;28(9):1283–8. doi:10.3346/jkms.2013.28.9.1283. PMID:24015031.
   PubMed Web of Science ®Google Scholar
• Health Insurance Review & Assessment Service. Korea National Health Insurance Reimbursement Medical Expenses, 2015. [2017 June 6]. http://www.google.co.kr/url?url=http://opendata.hira.or.kr/co.apndFile.dir/download.do%3FfileNm%3D%25EA%25B1%25B4%25EA%25B0%2595%25EB%25B3%25B4%25ED%2597%2598%25EC%259A%2594%25EC%2596%2591%25EA%25B8%2589%25EC%2597%25AC%25EB%25B9%2584%25EC%259A%25A9.pdf&rct=j&frm=1&q=&esrc=s&sa=U&ved=0ahUKEwjsx_LPipTOAhUMymMKHS2YCTAQFggmMAM&usg=AFQjCNGPZbp-ucGDg7LjPJ6Tb_L5ZNjFHg.
   Google Scholar
• Korean statistical information service (KOSIS). [assessed 2018 February 2]. http://www.index.go.kr/potal/main/EachDtlPageDetail.do?idx_cd=4027.
   Google Scholar
• Andrews NJ, Waight PA, Burbidge P, Pearce E, Roalfe L, Zancolli M, Slack M, Ladhani SN, Miller E, Goldblatt D. Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study. Lancet Infect Dis. 2014;14(9):839–46. doi:10.1016/S1473-3099(14)70822-9. PMID:25042756.
   PubMed Web of Science ®Google Scholar
• National Evidence-based Healthcare Collaborating Agency. Handbook for clinical practice guideline developer 2015. [2017 June 6]. http://www.neca.re.kr/center/researcher/book_view.jsp?boardNo=CA&seq=9436&q=626f6172644e6f3d4341.
   Google Scholar